Table 2. Randomized controlled trial with perioperative anti-HER2 agents in HER2+ gastric cancer and EGJ carcinoma.

NCT number	Study name	Phase	Setting	Treatment	Primary endpoint
NCT02581462	PETRARCA	II/III	Untreated GC and EGJ HER2+ ≥cT2 or cN+	Perioperative 5-fluorouracil+leucovorin+docetaxel+oxaliplatin+trastuzumab/pertuzumab	pCR (phase II), PFS (phase III)
NCT02205047	INNOVATION	II	Untreated GC and EGJ HER2+ stage Ib–III	Perioperative cisplatin+capecitabine/5-fluorouracil with or without trastuzumab or trastuzumab+pertuzumab	pCR

GC = gastric cancer; EGJ = esophagogastric junction; PFS = progression-free survival; pCR = pathological complete response.